U.S. Markets close in 6 hrs 23 mins
  • S&P 500

    4,177.39
    -8.08 (-0.19%)
     
  • Dow 30

    34,066.89
    -133.78 (-0.39%)
     
  • Nasdaq

    14,030.00
    -22.34 (-0.16%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.13
    0.00 (0.00%)
     
  • Gold

    1,770.50
    -9.70 (-0.54%)
     
  • Silver

    25.83
    -0.27 (-1.03%)
     
  • EUR/USD

    1.2031
    +0.0050 (+0.4211%)
     
  • 10-Yr Bond

    1.6150
    +0.0420 (+2.67%)
     
  • Vix

    17.19
    +0.62 (+3.74%)
     
  • GBP/USD

    1.3955
    +0.0115 (+0.8331%)
     
  • USD/JPY

    108.2370
    -0.5460 (-0.5019%)
     
  • BTC-USD

    56,430.74
    +1,764.93 (+3.23%)
     
  • CMC Crypto 200

    1,276.73
    -22.22 (-1.71%)
     
  • FTSE 100

    7,009.17
    -10.36 (-0.15%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Innoviva: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Innoviva (NASDAQ:INVA) increased in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 14.29% over the past year to $0.48, which beat the estimate of $0.40.

Revenue of $90,476,000 rose by 19.09% year over year, which beat the estimate of $74,500,000.

Looking Ahead

Innoviva hasn't issued any earnings guidance for the time being.

View more earnings on INVA

Revenue guidance hasn't been issued by the company for now.

Recent Stock Performance

Company's 52-week high was at $15.62

Company's 52-week low was at $7.58

Price action over last quarter: Up 15.67%

Company Overview

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes RELVAR/BREO/ELLIPTA, ANORO, ELLIPTA, TRELEGY, ELLIPTA, and others. The firm collaborates with and receives funding from GlaxoSmithKline.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.